New Delhi, July 28 -- The Drug Controller General of India (DCGI), is set to instruct states and Union territories to identify and take action against drugmakers failing to adhere to Good Manufacturing Practices (GMP), according to two official familiar with the matter.

GMP is meant to ensures consistent production and quality control, vital for patient safety, product effectiveness, and preventing fake drugs.

A recent revision of Schedule M GMP rules seeks to align India's quality standards with global benchmarks in a bid to boost the country's reputation as a reliable drug producer.

All large companies, with revenues exceeding Rs.250 crore, are implementing GMP while smaller firms received an extension until 31 December to make the n...